{"id":43022,"date":"2024-08-23T10:30:29","date_gmt":"2024-08-23T10:30:29","guid":{"rendered":"https:\/\/gulftimes.ae\/promising-lung-cancer-vaccine-trial-starts-in-uk\/"},"modified":"2024-08-23T10:30:29","modified_gmt":"2024-08-23T10:30:29","slug":"promising-lung-cancer-vaccine-trial-starts-in-uk","status":"publish","type":"post","link":"https:\/\/gulftimes.ae\/?p=43022","title":{"rendered":"Promising lung cancer vaccine trial starts in UK"},"content":{"rendered":"


\n<\/p>\n

\n

The treatment should specifically target cancer cells for destruction rather than healthy ones, hopefully meaning fewer side effects. <\/p>\n

It contains information about several markers found on the surface of lung cancer cells to teach the patient’s immune system what to find and fight. <\/p>\n

The BNT116 vaccine, made by German biotechnology company BioNTech, could be a game-changer, say experts. <\/p>\n

Prof Siow Ming Lee, who is clinical lead for the UK part of the trial, told the BBC’s Today programme: “We hope to kick-start this new era of mRNA cancer vaccine treatment for lung cancer.<\/p>\n

“Hopefully, in combination with the current standard treatment – immunotherapy and chemotherapy – we can provide an additional immune boost.”<\/p>\n

Mr Racz, from London, says he is open to trying new things. <\/p>\n

“I hope it will provide a defence against cancer cells. But I also thought that my participation in this research could help other people in future, and help this therapy become more widely available.<\/p>\n

“As a scientist myself, I know that science can only advance if people agree to participate in programmes like this.”<\/p>\n

Mr Racz, who works in artificial intelligence, was diagnosed with lung cancer after having some breathing problems that he thought might be asthma. <\/p>\n

A medical scan (for an unrelated issue) revealed a tumour on his right lung.<\/p>\n

NHS England national cancer director Dame Cally Palmer said shots like this one could be “revolutionary” in vaccinating people against their own cancers to prevent the disease returning.<\/p>\n

“A cancer diagnosis is very worrying, but access to groundbreaking trials \u2013 alongside other innovations to diagnose and treat cancers earlier \u2013 provides hope. <\/p>\n

“We expect to see thousands more patients taking part in trials over the next few years,” she said.<\/p>\n

The trial will recruit people with non-small cell lung cancer (NSCLC) from early-stage before surgery or radiotherapy, to late-stage disease or recurrent cancer – to have the jab alongside standard immunotherapy.<\/p>\n

The other UK hospitals taking part include:<\/p>\n

\n